Market Overview

Teva Vs Mylan: Wells Fargo Weighs In

Share:
Teva Vs Mylan: Wells Fargo Weighs In

The past year has been a rollercoaster ride for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) and its investors. But even with the stock down 48.6 percent in the past year, investors may have more downside ahead in 2018, according to Wells Fargo. 

The Analyst

Wells Fargo analyst David Maris downgraded Teva from Market Perform to Underperform and raised the price target from $12 to $17.

The Thesis

The market got it right when Teva shares initially tanked following major guidance and dividend cuts last year, Maris said in a note. (See the analyst's track record here.) 

But the stock has inexplicably risen roughly 80 percent from its 2017 lows, and Maris said there’s no fundamental justification for the move. In the downgrade note, Maris said dip buyers are misguided.

“We expect other generic Copaxones will emerge in 2018, pricing pressures will remain and Teva’s debt will be downgraded, and as such, we think the recent rally is a good time to sell shares and reassess things after Teva provides its 2018 update Feb. 8, 2018," the analyst said. 

In addition to the downgrade, Maris reduced his 2018 EPS estimate for Teva from $2.86 to $2.68, significantly lower than $3 consensus. The new estimates comes after Teva announced $3 billion in cost cuts over the next several years. Maris said he is not optimistic that these costs cuts and layoffs will have a meaningful impact on Teva’s bottom line given the company's number of fixed costs. 

While Teva may look like a better value than competitor Mylan NV (NASDAQ: MYL), Maris said Teva's long list of challenges and its massive debt load make Mylan a better play today. 

Price Action

Teva stock was down more than 2 percent at the time of publication Friday afternoon. 

Related Links:

A Look At Teva's Big Week

Credit Suisse Upgrades Teva After Job Cuts Announced

Latest Ratings for TEVA

DateFirmActionFromTo
Nov 2019UpgradesUnderweightNeutral
Nov 2019MaintainsNeutral
Oct 2019UpgradesHoldBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Davis MarisAnalyst Color Biotech Downgrades Price Target Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (MYL + TEVA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Argus Shares Eli Lilly's Optimism, Upgrades To Buy

7 Top Picks For 2018 And Their Corresponding ETFs